Significance of CD44 expression in head and neck cancer: A systemic review and meta-analysis

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Chen, Jianqiang ^a   Zhou, Jianding ^a   Lu, Jie ^a   Xiong, Hua ^a   Shi, Xueli ^a   Gong, Liang ^a  

^a Cixi Hospital Affiliated with Wenzhou Medical University   (China)

Author keywords

CD44 v6; Head and neck cancer; Pan CD44; Prognosis

Indexed keywords

CD44V6 ANTIGEN; CELL ANTIBODY; HERMES ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CLINICAL FEATURE; DISEASE FREE SURVIVAL; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INFORMATION RETRIEVAL; LARYNX CANCER; MEDLINE; META ANALYSIS (TOPIC); MOUTH CANCER; OVERALL SURVIVAL; PHARYNX CANCER; SYSTEMATIC REVIEW;

ANTIGENS, CD44; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM GRADING; NEOPLASM STAGING; ODDS RATIO; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84892414818     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-15     Document Type: Article

References (72)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: Canc J Clinician 2012, 62(1):10-29.
2. Kokko LL, Hurme S, Maula SM, Alanen K, Grenman R, Kinnunen I, Ventela S. Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma. Oral Oncol 2011, 47(6):510-516. 10.1016/j.oraloncology.2011.03.026, 21514878.
3. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Ann Rev Dev Biol 2007, 23:675-699.
4. Bomken S, Fiser K, Heidenreich O, Vormoor J. Understanding the cancer stem cell. Br J Canc 2010, 103(4):439-445.
5. Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, Tsai TH, Chou SH, Chien CS, Ku HH, Lo JF. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Canc Res: Offic J Am Assoc Canc Res 2008, 14(13):4085-4095.
6. Yu CC, Chang YC. Enhancement of cancer stem-like and epithelial-mesenchymal transdifferentiation property in oral epithelial cells with long-term nicotine exposure: reversal by targeting SNAIL. Toxicol Appl Pharmacol 2013, 266(3):459-469. 10.1016/j.taap.2012.11.023, 23219715.
7. Chen YS, Wu MJ, Huang CY, Lin SC, Chuang TH, Yu CC, Lo JF. CD133/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer. PloS One 2011, 6(11):e28053. 10.1371/journal.pone.0028053, 3225383, 22140506.
8. Trapasso S, Allegra E. Role of CD44 as a marker of cancer stem cells in head and neck cancer. Biol: Targets Ther 2012, 6:379-383.
9. Joshua B, Kaplan MJ, Doweck I, Pai R, Weissman IL, Prince ME, Ailles LE. Frequency of cells expressing CD44, a head and neck cancer stem cell marker: correlation with tumor aggressiveness. Head Neck 2012, 34(1):42-49. 10.1002/hed.21699, 21322081.
10. Chikamatsu K, Takahashi G, Sakakura K, Ferrone S, Masuyama K. Immunoregulatory properties of CD44+ cancer stem-like cells in squamous cell carcinoma of the head and neck. Head & neck 2011, 33(2):208-215. 10.1002/hed.21420, 3426231, 20848440.
11. van der Windt GJ, Schouten M, Zeerleder S, Florquin S, van der Poll T. CD44 is protective during hyperoxia-induced lung injury. Am J Respir Mol Biol 2011, 44(3):377-383.
12. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?. Nat Rev Canc 2011, 11(4):254-267.
13. Negi LM, Talegaonkar S, Jaggi M, Ahmad FJ, Iqbal Z, Khar RK. Role of CD44 in tumour progression and strategies for targeting. J Drug Target 2012, 20(7):561-573. 10.3109/1061186X.2012.702767, 22758394.
14. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990, 61(7):1303-1313. 10.1016/0092-8674(90)90694-A, 1694723.
15. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Canc 2010, 46(7):1271-1277.
16. Wibulswas A, Croft D, Pitsillides AA, Bacarese-Hamilton I, McIntyre P, Genot E, Kramer IM. Influence of epitopes CD44v3 and CD44v6 in the invasive behavior of fibroblast-like synoviocytes derived from rheumatoid arthritic joints. Arthritis Rheum 2002, 46(8):2059-2064. 10.1002/art.10421, 12209509.
17. Fehon RG, McClatchey AI, Bretscher A. Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol 2010, 11(4):276-287. 10.1038/nrm2866, 2871950, 20308985.
18. Lamontagne CA, Grandbois M. PKC-induced stiffening of hyaluronan/CD44 linkage; local force measurements on glioma cells. Exp Cell Res 2008, 314(2):227-236. 10.1016/j.yexcr.2007.07.013, 17698062.
19. Gonzalez-Moles MA, Bravo M, Ruiz-Avila I, Esteban F, Rodriguez-Archilla A, Gonzalez-Moles S, Arias B. Adhesion molecule CD44 as a prognostic factor in tongue cancer. Anticancer Res 2003, 23(6D):5197-5202.
20. Esteban F, Bravo JJ, Gonzalez-Moles MA, Bravo M, Ruiz-Avila I, Gil-Montoya JA. Adhesion molecule CD44 as a prognostic factor in laryngeal cancer. Anticancer Res 2005, 25(2A):1115-1121.
21. Kosunen A, Pirinen R, Ropponen K, Pukkila M, Kellokoski J, Virtaniemi J, Sironen R, Juhola M, Kumpulainen E, Johansson R, et al. CD44 expression and its relationship with MMP-9, clinicopathological factors and survival in oral squamous cell carcinoma. Oral Oncol 2007, 43(1):51-59. 10.1016/j.oraloncology.2006.01.003, 16798062.
22. Wang SJ, Earle C, Wong G, Bourguignon LY. Role of hyaluronan synthase 2 to promote CD44-dependent oral cavity squamous cell carcinoma progression. Head Neck 2013, 35(4):511-520. 10.1002/hed.22991, 22473523.
23. Mori S, Nose M, Morikawa H, Sato A, Saito T, Song ST, Tanda N, Teshima T. A novel evaluation system of metastatic potential of oral squamous cell carcinoma according to the histopathological and histochemical grading. Oral Oncol 1998, 34(6):549-557. 10.1016/S1368-8375(98)00048-7, 9930370.
24. Wang S, Qiang Y, Xiao K, Jiang S, Chen E. Expression of CD44s and CD44v6 in laryngeal squamous cell carcinoma and their significance. J Clin Oto (China) 2000, 14(10):3.
25. Rong XZ, Zhi WS, Ming CX. The immunohistochemical expression of CD44s and CD44v6 in oral squamous cell carcinomas. J Oral Maxillofac Surg 2001, 11(3):208-211.
26. Zhao SW, Sun BC, He J, Ye Q, Lin SZ, Sun A. The expression of CD44 and its significance in human laryngeal carcinoma. J Clin Oto (China) 2003, 17(3):3.
27. Qiu XX, Huang JF, Zhang ZX, Da P, Zhou R. The expression of CD44 and its clinical significance in human laryngeal carcinoma. Med J Comm 2006, 20(6):670-671.
28. Lu S, Tian J, Lv Z, Wang H, Bai X, Liu W, Li J, Xu W. The probable role of tumor stem cells for lymph node metastasis in supraglottic carcinoma. Pathol Oncol Res: POR 2011, 17(1):33-38.
29. Uwa N, Kataoka TR, Torii I, Sato A, Nishigami T, Song M, Daimon T, Saeki N, Sagawa K, Mouri T, et al. CD44 expression is related to poor prognosis of hypopharyngeal squamous cell carcinoma. Acta Oto-laryngologica 2011, 131(3):323-329.
30. Yuce I, Bayram A, Cagli S, Canoz O, Bayram S, Guney E. The role of CD44 and matrix metalloproteinase-9 expression in predicting neck metastasis of supraglottic laryngeal carcinoma. Am J Otolaryngol 2011, 32(2):141-146. 10.1016/j.amjoto.2010.01.001, 20434807.
31. Lindquist D, Ahrlund-Richter A, Tarjan M, Tot T, Dalianis T. Intense CD44 expression is a negative prognostic factor in tonsillar and base of tongue cancer. Anticancer Res 2012, 32(1):153-161.
32. Wang M, Xing L, Zhang C. Study in the Expression of CD44 in Nasopharyngeal Neoplasms and the Clinical Relationship. Tianjin Med J 2004, 32(9):3.
33. Song X, Peng J, Cai X, Hou F, Lin Q. Expression of CD44v6 protein in laryngeal squamous cell carcinoma. Chin J Otorhinolaryngol-Skull Base Surg 1999, 5(2):4.
34. Xu YP, Zhao XQ, Sommer K, Moubayed P. Correlation of matrix metalloproteinase-2, -9, tissue inhibitor-1 of matrix metalloproteinase and CD44 variant 6 in head and neck cancer metastasis. J Zhejiang Univ (Sci) 2003, 4(4):491-501. 10.1631/jzus.2003.0491, 12861629.
35. Liqun X, Lijia S, Huiyong J, Liu Q. Tissue microarray assay of CD44v6 and PCNA expression for oral squamous cell carcinomas and precancerous lesions and it sclinical significance. J Jinan Univ 2006, 27(6):8.
36. Staibano S, Merolla F, Testa D, Iovine R, Mascolo M, Guarino V, Castellone MD, Di Benedetto M, Galli V, Motta S, et al. OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome. Brit J Canc 2007, 97(11):1545-1551.
37. Huang S, Luo W, Wu S, Wang W, Chen X. Expression of PCNA and CD44V6 in laryngeal carcinoma. J Guangdong Medical Coll 2007, 2(2):3.
38. Lu J, Gao Y, Xiao Y, Jin D. Expression and clinical significance of CD44v6 in tissues of laryngeal and hypopharyngeal squamous cell carcinoma. J Harbin Med Univ 2008, 42(2):5.
39. Gao Y. The expression and its significance of CD44v6 in human laryngeal and hypopharyngeal squamous cell carcinoma. Chi Med Herald 2009, 6(1):2.
40. Guo X, Li F X, Feng S, Li X, Pan Z, Guan C, Wang Y, Yang H, Jiang X. Expression of gene BRMS1 and CD44v6 protein in supraglottic laryngeal carcinoma and its clinical significance. J Clin Otorhinolaryngol Head Neck Surg (China) 2009, 23(6):6.
41. Zhang R, Fan LV, Mu S, Xie X, Zhang M, Zhao C, Chang Q. Expression of CD44v6 in human oral squamous cell carcinoma. J Oral Sci Res 2011, 27(9):4.
42. Masuda M, Kuratomi Y, Shiratsuchi H, Nakashima T, Naonobu K, Komiyama S. Decreased CD44H expression in early-stage tongue carcinoma associates with late nodal metastases following interstitial brachytherapy. Head Neck 2000, 22(7):662-665. 10.1002/1097-0347(200010)22:7<662::AID-HED4>3.0.CO;2-O, 11002320.
43. Kawano T, Nakamura Y, Yanoma S, Kubota A, Furukawa M, Miyagi Y, Tsukuda M. Expression of E-cadherin, and CD44s and CD44v6 and its association with prognosis in head and neck cancer. Auris Nasus Larynx 2004, 31(1):35-41. 10.1016/j.anl.2003.09.005, 15041052.
44. Bankfalvi A, Krassort M, Buchwalow IB, Vegh A, Felszeghy E, Piffko J. Gains and losses of adhesion molecules (CD44, E-cadherin, and beta-catenin) during oral carcinogenesis and tumour progression. J Pathol 2002, 198(3):343-351. 10.1002/path.1204, 12375267.
45. Ma D, Yuan L, Zhao Y, Zhou X, Li C, Liu L. Relationship study between KAI1, CD44v3 expressions and laryngeal carcinoma. J Shandong Med Coll 2009, 31(2):4.
46. Ue T, Yokozaki H, Kagai K, Higashikawa K, Yasui W, Sugiyama M, Tahara E, Ishikawa T. Reduced expression of the CD44 variant exons in oral squamous cell carcinoma and its relationship to metastasis. J Oral Pathol Med: offi Publ Int Assoc Oral Pathol Am Acad Pathol 1998, 27(5):197-201.
47. Fonseca I, Pereira T, Rosa-Santos J, Soares J. Expression of CD44 isoforms in squamous cell carcinoma of the border of the tongue: A correlation with histological grade, pattern of stromal invasion, and cell differentiation. J Surg Oncol 2001, 76(2):115-120. 10.1002/1096-9098(200102)76:2<115::AID-JSO1021>3.0.CO;2-9, 11223837.
48. Kwong LN, Dove WF. APC and its modifiers in colon cancer. Adv Exp Med Biol 2009, 656:85-106. 10.1007/978-1-4419-1145-2_8, 3754875, 19928355.
49. Biddle A, Gammon L, Fazil B, Mackenzie IC. CD44 staining of cancer stem-like cells is influenced by down-regulation of CD44 variant isoforms and up-regulation of the standard CD44 isoform in the population of cells that have undergone epithelial-to-mesenchymal transition. PloS one 2013, 8(2):e57314. 10.1371/journal.pone.0057314, 3577706, 23437366.
50. Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J, Cheng C. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Investig 2011, 121(3):1064-1074. 10.1172/JCI44540, 3049398, 21393860.
51. Krishnamachary B, Penet MF, Nimmagadda S, Mironchik Y, Raman V, Solaiyappan M, Semenza GL, Pomper MG, Bhujwalla ZM. Hypoxia regulates CD44 and its variant isoforms through HIF-1alpha in triple negative breast cancer. PloS One 2012, 7(8):e44078. 10.1371/journal.pone.0044078, 3429433, 22937154.
52. Rodrigo JP, Dominguez F, Alvarez C, Herrero A, Suarez C. Expression of E-cadherin, CD44s, and CD44v6 in laryngeal and pharyngeal carcinomas. Am J Otolaryngol 2003, 24(6):384-389. 10.1016/S0196-0709(03)00082-6, 14608570.
53. Piffko J, Bankfalvi A, Klauke K, Dreier R, Joos U, Bocker W, Schmid KW. Unaltered strong immunohistochemical expression of CD44-v6 and -v5 isoforms during development and progression of oral squamous cell carcinomas. J Oral Pathol Med: Offic Publ Int Ass Oral Pathologists Am Acad Oral Pathol 1996, 25(9):502-506.
54. Rajarajan A, Stokes A, Bloor BK, Ceder R, Desai H, Grafstrom RC, Odell EW. CD44 expression in oro-pharyngeal carcinoma tissues and cell lines. PloS One 2012, 7(1):e28776. 10.1371/journal.pone.0028776, 3252301, 22242150.
55. Lin JT, Chang TH, Chang CS, Wang WH, Su BW, Lee KD, Chang PJ. Prognostic value of pretreatment CD44 mRNA in peripheral blood of patients with locally advanced head and neck cancer. Oral Oncol 2010, 46(5):e29-e33. 10.1016/j.oraloncology.2010.02.011, 20227328.
56. Okamoto I, Tsuiki H, Kenyon LC, Godwin AK, Emlet DR, Holgado-Madruga M, Lanham IS, Joynes CJ, Vo KT, Guha A, et al. Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol 2002, 160(2):441-447. 10.1016/S0002-9440(10)64863-8, 1850643, 11839564.
57. Stamenkovic I, Yu Q. Shedding light on proteolytic cleavage of CD44: the responsible sheddase and functional significance of shedding. J Investig Dermatol 2009, 129(6):1321-1324. 10.1038/jid.2009.13, 2759693, 19434087.
58. Okamoto I, Kawano Y, Murakami D, Sasayama T, Araki N, Miki T, Wong AJ, Saya H. Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J Cell Biol 2001, 155(5):755-762. 10.1083/jcb.200108159, 2150876, 11714729.
59. Lammich S, Okochi M, Takeda M, Kaether C, Capell A, Zimmer AK, Edbauer D, Walter J, Steiner H, Haass C. Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Abeta-like peptide. J Biol Chem 2002, 277(47):44754-44759. 10.1074/jbc.M206872200, 12223485.
60. Anderegg U, Eichenberg T, Parthaune T, Haiduk C, Saalbach A, Milkova L, Ludwig A, Grosche J, Averbeck M, Gebhardt C, et al. ADAM10 is the constitutive functional sheddase of CD44 in human melanoma cells. J Investig Dermatol 2009, 129(6):1471-1482. 10.1038/jid.2008.323, 18971959.
61. Takamune Y, Ikebe T, Nagano O, Nakayama H, Ota K, Obayashi T, Saya H, Shinohara M. ADAM-17 associated with CD44 cleavage and metastasis in oral squamous cell carcinoma. Virchows Archiv: Int J Pathol 2007, 450(2):169-177.
62. Takamune Y, Ikebe T, Nagano O, Shinohara M. Involvement of NF-kappaB-mediated maturation of ADAM-17 in the invasion of oral squamous cell carcinoma. Biochem Biophys Res Commun 2008, 365(2):393-398. 10.1016/j.bbrc.2007.11.010, 17999917.
63. Ko SY, Lin SC, Wong YK, Liu CJ, Chang KW, Liu TY. Increase of disintergin metalloprotease 10 (ADAM10) expression in oral squamous cell carcinoma. Canc lett 2007, 245(1-2):33-43.
64. Cromer A, Carles A, Millon R, Ganguli G, Chalmel F, Lemaire F, Young J, Dembele D, Thibault C, Muller D, et al. Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. Oncogene 2004, 23(14):2484-2498. 10.1038/sj.onc.1207345, 14676830.
65. Oliveira DT, Odell EW. Expression of CD44 variant exons by normal oral epithelia. Oral Oncol 1997, 33(4):260-262. 10.1016/S0964-1955(97)00081-X, 9307715.
66. Franzmann EJ, Reategui EP, Pedroso F, Pernas FG, Karakullukcu BM, Carraway KL, Hamilton K, Singal R, Goodwin WJ. Soluble CD44 is a potential marker for the early detection of head and neck cancer. Canc Epidemiol Biomark Preve: Publ Am Assoc Canc Res, Cosponsored Am Soc Prev Oncol 2007, 16(7):1348-1355.
67. Pereira LH, Adebisi IN, Perez A, Wiebel M, Reis I, Duncan R, Goodwin WJ, Hu JJ, Lokeshwar VB, Franzmann EJ. Salivary markers and risk factor data: a multivariate modeling approach for head and neck squamous cell carcinoma detection. Canc Biomarkers : Dection A of Dis markers 2011, 10(5):241-249.
68. Hsu KH, Tsai HW, Lin PW, Hsu YS, Shan YS, Lu PJ. Clinical implication and mitotic effect of CD44 cleavage in relation to osteopontin/CD44 interaction and dysregulated cell cycle protein in gastrointestinal stromal tumor. Ann Surg Oncol 2010, 17(8):2199-2212. 10.1245/s10434-010-0927-1, 20146103.
69. Margaritescu C, Pirici D, Simionescu C, Stepan A. The utility of CD44, CD117 and CD133 in identification of cancer stem cells (CSC) in oral squamous cell carcinomas (OSCC). Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 2011, 52(3 Suppl):985-993.
70. Su J, Xu XH, Huang Q, Lu MQ, Li DJ, Xue F, Yi F, Ren JH, Wu YP. Identification of cancer stem-like CD44+ cells in human nasopharyngeal carcinoma cell line. Arch Med Res 2011, 42(1):15-21. 10.1016/j.arcmed.2011.01.007, 21376257.
71. Lun SW, Cheung ST, Cheung PF, To KF, Woo JK, Choy KW, Chow C, Cheung CC, Chung GT, Cheng AS, et al. CD44+ cancer stem-like cells in EBV-associated nasopharyngeal carcinoma. PloS one 2012, 7(12):e52426. 10.1371/journal.pone.0052426, 3528656, 23285037.
72. Janisiewicz AM, Shin JH, Murillo-Sauca O, Kwok S, Le QT, Kong C, Kaplan MJ, Sunwoo JB. CD44(+) cells have cancer stem cell-like properties in nasopharyngeal carcinoma. Int Forum Allergy & Rhinology 2012, 2(6):465-470.